Trial Profile
A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Dendritic cell vaccines (Primary) ; Interferon alpha-2b (Primary) ; Rintatolimod (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Colon cancer; Colorectal cancer; Mesothelioma; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jul 2021 Status changed from no longer recruiting to discontinued as per results published in the Annals of Surgical Oncology
- 09 Jul 2021 Results (N=46) of an evaluable data analysis published in the Annals of Surgical Oncology
- 26 Dec 2018 Planned End Date changed from 1 Dec 2018 to 18 Feb 2019.